Biotechnology Research · England
Our mission is to radically improve outcomes for patients with cancer, infectious diseases and autoimmune conditions. Through bringing together a team of visionary leaders with some of the best track records in R&D, we are pioneering the next generation of immunotherapies and delivering transformative immunomodulating medicines. Engineered from T-cell receptors (TCRs), our ImmTAX (Immune Mobilizing Monoclonal TCRs Against X disease) molecules have the potential to overcome the limitations of the natural immune system. Already, we’ve seen how this technology can enable T cells to recognize and eliminate virally-infected or cancerous cells. We’ve also seen how our technology can be used to stop T cells from attacking healthy cells, as is the case in autoimmune diseases. Using this science, we are pioneering and delivering first-in-class biological therapies. Watch how our modular T cell receptor technology regulates the immune system up or down to target cancer, infectious diseases, and autoimmune diseases.